Endocrinology and Metabolism10.3803/enm.2014.29.3.2802014293280Early Prediction of Long-Term Response to Cabergoline in Patients with MacroprolactinomasYoungki Lee, Cheol Ryong Ku, Eui-Hyun Kim, Jae Won Hong, Eun Jig Lee, Sun Ho Kim,,
Clinical Endocrinology10.1046/j.1365-2265.2000.01137.x2000535595-599Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomasL. D. George, N. Nicolau, M. F. Scanlon, J. S. Davies,,
Clinical Endocrinology10.1111/cen.132402016862207-213Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawalShinya Watanabe, Hiroyoshi Akutsu, Shingo Takano, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroaki Suzuki, Akira Matsumura,,
Yearbook of Endocrinology10.1016/s0084-3741(10)79605-020102010345-346Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patientsW.H. Ludlam,
Journal of the Endocrine Society10.1210/js.2017-00038201713221-230Cabergoline Tapering Is Almost Always Successful in Patients With MacroprolactinomasAnne-Cécile Paepegaey, Sylvie Salenave, Peter Kamenicky, Luigi Maione, Sylvie Brailly-Tabard, Jacques Young, Philippe Chanson
Yearbook of Endocrinology10.1016/s0084-3741(09)79375-820092009278-279Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomasW.H. Ludlam,
Clinical Neurophysiology10.1016/j.clinph.2006.11.12920071184e53Early intervention in parkinson’s disease with cabergoline – Results of an open-label long-term trial with focus on sleep disturbancesW. Jost, M. Ueberall,
Endocrine10.1007/s12020-020-02557-12020721216-222Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicatedLukas Andereggen, Janine Frey, Emanuel Christ,,
International Journal of Gynecology & Obstetrics10.1016/j.ijgo.2007.04.027200799161-62Cabergoline treatment of pregnant women with macroprolactinomasM. Laloi-Michelin, N. Ciraru-Vigneron, T. Meas,,,,
European Journal of Internal Medicine10.1016/j.ejim.2008.11.0122009204387-393Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonistsMarleen Kars, Alberto M. Pereira, Johannes W. Smit, Johannes A. Romijn,